Morphine

Introduction Overview

Generic Name

Morphine

Brand Name

Kadian, MS Contin

Dosage Form

Oral capsule (extended release), oral concentrate, oral solution, oral tablet (immediate and extended release), intravenous, suppository, epidural

Drug Class

Opioids (narcotic analgesics)

Pharmacokinetics

Morphine exhibits complex pharmacokinetic properties influenced by its physicochemical characteristics and the route of administration.

Absorption:
Morphine is well absorbed via multiple routes including oral, intravenous, subcutaneous, and epidural. Oral bioavailability ranges between 20% to 40%, significantly affected by extensive first-pass metabolism in the liver, which reduces systemic availability. The time to peak plasma concentration after oral administration is typically between 30 to 60 minutes for immediate-release formulations, whereas extended-release forms produce sustained plasma concentrations over 8 to 24 hours. Absorption can be influenced by gastrointestinal factors such as motility, pH, and presence of food, with food generally having minimal impact on morphine pharmacokinetics.

Distribution:
Once absorbed, morphine is widely distributed throughout the body, with a volume of distribution approximating 2 to 5 L/kg, indicating extensive tissue uptake. It readily crosses the blood-brain barrier to exert central analgesic effects, although penetration is less efficient than lipophilic opioids. Morphine also crosses the placenta and is excreted into breast milk. Approximately 35% to 40% of plasma morphine is bound to plasma proteins, primarily albumin, which may be altered in disease states affecting protein levels. Morphine's distribution to peripheral tissues and central nervous system is critical for its analgesic action and side effect profile.

Metabolism:
Morphine undergoes extensive hepatic metabolism primarily by conjugation with glucuronic acid, forming two major metabolites: morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). M3G is inactive but may contribute to neurotoxic effects, while M6G possesses potent analgesic activity, contributing to morphine's effect and potential toxicity. Hepatic metabolism is mediated by UDP-glucuronosyltransferase enzymes, and metabolism can be influenced by hepatic function, age, and drug interactions. Minor metabolic pathways include N-demethylation to normorphine. Renal impairment can lead to accumulation of active metabolites, enhancing narcotic effects and side effects.

Elimination:
Morphine and its metabolites are primarily eliminated by renal excretion. The elimination half-life of morphine is approximately 2 to 4 hours, although metabolites, especially M6G, have longer half-lives and accumulate in renal dysfunction. About 10% to 20% of morphine dose is excreted unchanged in urine, with the remainder excreted as glucuronide conjugates. Fecal elimination is minimal but may occur via biliary excretion. Factors such as age, renal function, and co-administered drugs can significantly alter morphine clearance, necessitating dosing adjustments in specific populations.

Dosage Forms

Available Dosage Forms:
Morphine is available in multiple formulations to accommodate various clinical needs. These include oral capsules with extended-release characteristics (available in strengths of 10 mg/12 to 24 hr; 100 mg/12 to 24 hr; 120 mg/24 hours; 20 mg/12 to 24 hr; 30 mg/12 to 24 hr; 30 mg/24 hours; 45 mg/24 hours; 50 mg/12 to 24 hr; 60 mg/12 to 24 hr; 60 mg/24 hours; 75 mg/24 hours; 80 mg/12 to 24 hr; 90 mg/24 hours), oral concentrate formulations (20 mg/mL), oral solutions available in various strengths (10 mg/0.5 mL; 10 mg/5 mL; 20 mg/5 mL), immediate-release oral tablets (15 mg; 30 mg), and extended-release oral tablets (100 mg/8 to 12 hr; 15 mg/8 to 12 hr; 200 mg/8 to 12 hr; 30 mg/8 to 12 hr; 60 mg/8 to 12 hr). Other formulations include intravenous injections, suppositories, and epidural preparations not detailed here.

Dosages for Adults and Adolescents:
Dosing is highly individualized based on pain severity, prior opioid use, and patient factors. Immediate-release formulations typically start at 15 to 30 mg orally every 4 hours as needed for pain, whereas extended-release capsules or tablets are dosed from 10 mg to 200 mg every 8 to 24 hours. Titration is necessary to balance analgesia with side effects, particularly respiratory depression. Oral concentration dosing must be carefully measured using appropriate devices. In severe pain, intravenous or epidural administration may be employed with clinician supervision.

Specific Patient Populations:
Special considerations apply to populations such as elderly, patients with renal or hepatic impairment, and opioid-naive individuals. Dose adjustments and cautious titration are necessary to avoid accumulation and adverse effects. In renal impairment, accumulation of active metabolites requires lower dosing and careful monitoring. Pregnant and breastfeeding women are advised against morphine use due to risks of neonatal withdrawal and toxicity. Pediatric dosing must be carefully calculated based on weight and clinical condition. Extended-release formulations are contraindicated in opioid-naive patients due to overdose risk.

Mechanism Of Action

Morphine functions as a potent opioid analgesic by selectively binding to and activating the mu-opioid receptors (MOR), which are G-protein-coupled receptors abundantly expressed in the central and peripheral nervous systems. Upon binding, morphine induces conformational changes that inhibit adenylate cyclase activity, reducing cyclic AMP production and leading to decreased neuronal excitability.

At the cellular level, activation of mu-opioid receptors results in opening of potassium channels and closing of voltage-gated calcium channels. This hyperpolarizes neurons and inhibits neurotransmitter release, particularly of excitatory neurotransmitters like substance P, glutamate, and calcitonin gene-related peptide in pain pathways. These biochemical interactions attenuate the transmission of nociceptive signals from peripheral nerves to the central nervous system, effectively reducing the perception and emotional response to pain.

Morphine’s action in key brain regions including the thalamus, limbic system, and brainstem modulates the affective and autonomic responses to pain, also contributing to sedation and euphoria. Unlike some synthetic opioids with high lipid solubility, morphine crosses the blood-brain barrier less readily, leading to a slower onset but prolonged duration of analgesia.

Clinically, the mechanism of morphine translates into profound relief of moderate to severe acute and chronic pain, including cancer pain and post-surgical pain. Compared with other opioids such as fentanyl or oxycodone, morphine’s active metabolite M6G significantly contributes to its analgesic profile but also potentiates adverse effects, emphasizing the need for clinical monitoring. Extensive research supports its efficacy; however, tolerance, physical dependence, and risk of respiratory depression necessitate cautious, individualized dosing.

Pharmacological Actions

Potent analgesic effect through mu-opioid receptor agonism
Sedative and anxiolytic properties decreasing the emotional response to pain
Antitussive (cough suppressant) effects via brainstem receptors
Euphoria induction through central nervous system effects
Reduction of gastrointestinal motility causing constipation
Respiratory depression due to brainstem respiratory center inhibition
Miosis (pupillary constriction) by central parasympathetic stimulation
Modulation of autonomic functions including decreased heart rate and blood pressure
Possible immunosuppressive effects with chronic use
Induction of nausea and vomiting via chemoreceptor trigger zone stimulation
Physical dependence and addiction potential due to neuroadaptive changes
Alteration of hypothalamic-pituitary-adrenal axis function
Suppression of hormonal secretions such as cortisol and sex hormones
Influence on neurotransmitters including dopamine and serotonin pathways
Tolerance development requiring dose escalation for sustained analgesia

Therapeutic Or Clinical Uses

Management of moderate to severe acute pain unresponsive to non-opioid analgesics
Treatment of chronic pain including cancer-related pain
Perioperative analgesia during and after surgical procedures
Palliative care pain control for terminal illnesses
Management of pain associated with myocardial infarction
Epidural and intrathecal analgesia for labor and delivery pain management
Adjunct to anesthesia for induction and maintenance
Treatment of dyspnea associated with end-stage heart failure or pulmonary edema
Relief of severe chronic noncancer pain under specialist supervision
Suppressing severe cough in certain clinical contexts
Use in opioid substitution therapy for opioid dependence management (off-label)
Reduction of severe pain associated with trauma
Analgesia in patients with burns requiring significant pain control
Management of neonatal abstinence syndrome symptoms (under controlled conditions)
Treatment in hospice and end-of-life care to ensure patient comfort

Side Or Adverse Effects

Drowsiness and sedation leading to impaired alertness
Respiratory depression with risk of apnea and hypoxia
Nausea and vomiting caused by activation of the chemoreceptor trigger zone
Constipation due to decreased gastrointestinal motility
Pruritus and sweating from histamine release
Dizziness and orthostatic hypotension caused by vasodilation
Miosis leading to 'pinpoint pupils'
Urinary retention due to effects on bladder sphincter muscles
Euphoria occasionally progressing to dysphoria or hallucinations
Physical dependence and withdrawal syndrome upon abrupt cessation
Bradycardia and hypotension in susceptible individuals
Allergic reactions including rash, hives, and anaphylaxis in rare cases
Increased intracranial pressure through CO2 retention
Tolerance development necessitating dose adjustment
Risk of serotonin syndrome when combined with serotonergic agents

Precautions

Use cautiously in patients with respiratory disorders such as COPD or sleep apnea
Avoid use in patients with head injury or increased intracranial pressure
Monitor closely in individuals with impaired hepatic or renal function
Assess for history of substance abuse or opioid addiction before prescribing
Prevent use in patients with gastrointestinal obstruction or paralytic ileus
Dose adjustments recommended in elderly or debilitated patients to minimize sedation
Avoid abrupt discontinuation to prevent withdrawal symptoms
Caution when coadministered with CNS depressants due to additive sedation risk
Monitor for serotonin syndrome signs when combined with antidepressants
Use during pregnancy requires risk-benefit evaluation; potential neonatal withdrawal
Advise against breastfeeding due to risk of opioid toxicity in infants
Storage in secure location to prevent misuse or accidental ingestion
Educate patients on avoidance of alcohol and other sedatives during therapy
Careful titration required to balance efficacy and adverse effects
Avoid driving or operating heavy machinery until effects of the drug are known

Warnings

Contraindicated in severe asthma or respiratory depression
Risk of addiction, abuse, and misuse leading to overdose and death
Fatal respiratory depression may occur, especially during initiation or dose increases
Use with alcohol or other CNS depressants increases fatal overdose risk
Neonatal opioid withdrawal syndrome possible with prolonged maternal use
Do not crush, chew, or dissolve extended-release formulations to prevent overdose
Risk of life-threatening interactions with monoamine oxidase inhibitors (MAOIs)
Morphine overdose symptoms include extreme drowsiness, slow breathing, and pinpoint pupils
Potential for serotonin syndrome when combined with serotonergic drugs
Caregivers should have access to naloxone for emergency opioid overdose reversal
Severe hypotension and syncope can occur during therapy
Use cautiously in patients with head injury or increased intracranial pressure
Avoid prescribing in bowel obstruction or paralytic ileus
Risk of adrenal insufficiency with prolonged use
Keep out of reach of children to prevent accidental ingestion and fatal overdose

Contraindication

Known hypersensitivity or allergic reaction to morphine or other opioids
Severe respiratory depression or acute asthma attack
Paralytic ileus or gastrointestinal obstruction
Use within 14 days of monoamine oxidase inhibitors (MAOIs)
Severe bronchial asthma or hypercapnia
Concurrent use with alcohol or CNS depressants without medical supervision
Significant respiratory disorders without ability for monitoring
Known or suspected gastrointestinal obstruction
Patients with increased intracranial pressure where respiratory depression is hazardous
Opioid-naive patients at high risk of respiratory compromise for extended-release forms
Use in patients with acute alcoholism or delirium tremens
Myasthenia gravis due to risk of respiratory compromise
Severe hepatic or renal impairment without appropriate dose adjustment
Concomitant use with other drugs contraindicated due to pharmacodynamic interactions
Pregnancy unless potential benefits outweigh risks due to neonatal withdrawal risk

Drug Interactions

Central nervous system depressants (e.g., benzodiazepines, barbiturates) increase sedation and respiratory depression risk
Monoamine oxidase inhibitors (MAOIs) can precipitate severe hypertension or serotonin syndrome when combined
Other opioids or opioid-containing medications can enhance adverse effects and potential overdose
Alcohol consumption synergistically increases risk of respiratory depression and death
Anticholinergic agents may exacerbate opioid-induced constipation and urinary retention
Cimetidine, verapamil, and quinidine may inhibit morphine metabolism, increasing effects
Stimulant medications or serotonergic drugs increase the risk of serotonin syndrome
Muscle relaxants potentiate CNS depressant effects leading to increased sedation
Certain antiemetics and antidepressants may alter morphine pharmacodynamics
Drugs affecting cytochrome P450 pathways may alter morphine metabolism indirectly
MAOI use within past 14 days is contraindicated due to risk of hypertensive crisis
Herbal supplements like St. John’s Wort may reduce morphine efficacy via induction of metabolism
Combination with drugs causing QT prolongation should be monitored cautiously
Co-administration with opioid antagonists (e.g., naloxone) may precipitate withdrawal symptoms
Use with diuretics may alter volume status and electrolyte balance, affecting drug safety

Preparations Of The Drug

Oral Capsules (Extended Release) in multiple strengths: 10 mg/12 to 24 hr; 20 mg/12 to 24 hr; 30 mg/12 to 24 hr; 30 mg/24 hr; 45 mg/24 hr; 50 mg/12 to 24 hr; 60 mg/12 to 24 hr; 60 mg/24 hr; 75 mg/24 hr; 80 mg/12 to 24 hr; 90 mg/24 hr; 100 mg/12 to 24 hr; 120 mg/24 hr
Oral Tablets (Immediate and Extended Release) including 15 mg and 30 mg immediate release; Extended release at 15 mg/8–12 hr, 30 mg/8–12 hr, 60 mg/8–12 hr, 100 mg/8–12 hr, and 200 mg/8–12 hr
Oral Concentrate solution at 20 mg/mL for flexible dosing
Oral Solutions in strengths of 10 mg/0.5 mL, 10 mg/5 mL, and 20 mg/5 mL
Injectable formulations for intravenous, subcutaneous, and intramuscular use (not detailed here)
Suppositories for rectal administration available in various strengths
Epidural preparations for spinal analgesia under medical supervision
Extended-release formulations designed to provide controlled, sustained plasma concentrations for chronic pain
Immediate-release forms used for breakthrough pain or initial titration
Commercial preparations subject to regulatory approval and prescribing guidelines to minimize abuse
Availability of generic and brand-name products (e.g., MS Contin, Kadian, Roxanol)
Supplied with calibrated dosing devices for oral liquids to ensure accurate administration
Regularly updated prescribing information with risk mitigation strategies including REMS programs
Preservation using appropriate excipients ensuring stability and patient acceptability
Formulation considerations to prevent misuse such as abuse-deterrent technologies in extended-release forms